Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (12310)	7/12/2004 10:48:43 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 52153

Well Peter, >>There again I'd bet that a statin plus Niaspan will do more for mortality than a statin plus another cholesterol-lowering agent. I hope you are right. I'm taking Advicor and Niaspan. (Both KOSP drugs) If you are wrong, can my heirs sue a lawyer for medical malpractice? <g> ij

To: Biomaven who wrote (12310)	7/12/2004 11:12:42 PM
From: tom pope	Read Replies (1) \| Respond to of 52153

epidemiological data suggesting that low cholesterol in old people is bad Wasn't there also data a few years ago suggesting that low absolute cholesterol levels in young, fit people was bad, possibly because such people were risk takers and were more likely to drive their mountain bikes off precipices than sedentary couch potato types?

To: Biomaven who wrote (12310)	7/14/2004 6:00:17 AM
From: Henry Niman	Respond to of 52153

Peter, I will be posting more information at recombinomics.com but recombination is the chief driver of rapid viral evolution which has some very practical consequences for vaccine development for HIV, influenza, SARS, WNV (including the ability to make vaccines BEFORE viruses emerge).